CRISPR Therapeutics CRSP Proceeds from disposal of certain strategic investments

Proceeds from disposal of certain strategic investments at other companies

Jackson FinancialJXN

$16M+300%

First American FinancialFAF

$1.4M-90.7%

AllstateALL

$4.06B+188%

The Hanover Insurance GroupTHG

$38.3M+86.8%

Western Alliance BancorporationWAL

$0-100%

MTD

Matador ResourcesMTDR

$5.61M+81.3%

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Enterprise value$5.69B+69.8%

P/S1,298.3×+1,208×

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi.

The official record: CRISPR Therapeutics’s 10-K, filed February 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's proceeds from disposal of certain strategic investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's proceeds from disposal of certain strategic investments?: CRISPR Therapeutics (CRSP) reported proceeds from disposal of certain strategic investments of $175.5K in Q4 2025.